Yun Zhong
Stock Analyst at Wedbush
(3.15)
# 1,191
Out of 5,058 analysts
42
Total ratings
51.35%
Success rate
1.27%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Yun Zhong
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ASND Ascendis Pharma | Reiterates: Outperform | $220 | $212.15 | +3.70% | 3 | Nov 18, 2025 | |
| WVE Wave Life Sciences | Maintains: Outperform | $18 → $20 | $6.88 | +190.70% | 2 | Nov 11, 2025 | |
| KROS Keros Therapeutics | Maintains: Neutral | $15 → $16 | $16.86 | -5.10% | 3 | Nov 6, 2025 | |
| IRD Opus Genetics | Initiates: Outperform | $8 | $1.86 | +330.11% | 1 | Oct 29, 2025 | |
| PTGX Protagonist Therapeutics | Maintains: Outperform | $70 → $86 | $85.13 | +1.02% | 3 | Oct 28, 2025 | |
| MLTX MoonLake Immunotherapeutics | Maintains: Outperform | $80 → $18 | $13.54 | +32.94% | 2 | Sep 30, 2025 | |
| PASG Passage Bio | Maintains: Outperform | $3 → $40 | $7.88 | +407.61% | 3 | Aug 13, 2025 | |
| SGMT Sagimet Biosciences | Initiates: Outperform | $28 | $7.85 | +256.69% | 1 | Aug 11, 2025 | |
| VYGR Voyager Therapeutics | Maintains: Outperform | $9 → $8 | $4.16 | +92.31% | 2 | Aug 7, 2025 | |
| CAMP Camp4 Therapeutics | Initiates: Outperform | $8 | $3.73 | +114.48% | 1 | May 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $32 | $2.88 | +1,011.11% | 2 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $12 | $10.16 | +18.11% | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 → $28 | $3.60 | +677.78% | 2 | Feb 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.01 | - | 2 | Feb 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $16 | $9.73 | +64.44% | 1 | Jan 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $125 → $160 | $16.39 | +876.21% | 11 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $46 | $27.95 | +64.58% | 1 | Jun 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $1.81 | +452.49% | 1 | May 5, 2021 |
Ascendis Pharma
Nov 18, 2025
Reiterates: Outperform
Price Target: $220
Current: $212.15
Upside: +3.70%
Wave Life Sciences
Nov 11, 2025
Maintains: Outperform
Price Target: $18 → $20
Current: $6.88
Upside: +190.70%
Keros Therapeutics
Nov 6, 2025
Maintains: Neutral
Price Target: $15 → $16
Current: $16.86
Upside: -5.10%
Opus Genetics
Oct 29, 2025
Initiates: Outperform
Price Target: $8
Current: $1.86
Upside: +330.11%
Protagonist Therapeutics
Oct 28, 2025
Maintains: Outperform
Price Target: $70 → $86
Current: $85.13
Upside: +1.02%
MoonLake Immunotherapeutics
Sep 30, 2025
Maintains: Outperform
Price Target: $80 → $18
Current: $13.54
Upside: +32.94%
Passage Bio
Aug 13, 2025
Maintains: Outperform
Price Target: $3 → $40
Current: $7.88
Upside: +407.61%
Sagimet Biosciences
Aug 11, 2025
Initiates: Outperform
Price Target: $28
Current: $7.85
Upside: +256.69%
Voyager Therapeutics
Aug 7, 2025
Maintains: Outperform
Price Target: $9 → $8
Current: $4.16
Upside: +92.31%
Camp4 Therapeutics
May 27, 2025
Initiates: Outperform
Price Target: $8
Current: $3.73
Upside: +114.48%
May 16, 2025
Reiterates: Outperform
Price Target: $32
Current: $2.88
Upside: +1,011.11%
Nov 5, 2024
Initiates: Outperform
Price Target: $12
Current: $10.16
Upside: +18.11%
Feb 9, 2023
Maintains: Buy
Price Target: $35 → $28
Current: $3.60
Upside: +677.78%
Feb 2, 2023
Downgrades: Neutral
Price Target: n/a
Current: $4.01
Upside: -
Jan 18, 2023
Maintains: Buy
Price Target: $14 → $16
Current: $9.73
Upside: +64.44%
Dec 22, 2022
Maintains: Buy
Price Target: $125 → $160
Current: $16.39
Upside: +876.21%
Jun 15, 2021
Initiates: Buy
Price Target: $46
Current: $27.95
Upside: +64.58%
May 5, 2021
Initiates: Buy
Price Target: $10
Current: $1.81
Upside: +452.49%